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Cost-eﬀ ectiveness of community-based strategies for HIV
In 2013, 2·1 million people became infected with HIV, 
1·5 million died from AIDS, and 35 million continued to 
live with HIV infection,1 despite the existence of highly 
eﬀ ective interventions (eg, antiretroviral therapy) that 
can reduce HIV transmission by 96%.2 An AIDS-free 
generation is no longer a theoretical conjecture, but it is 
not the reality either.
In The Lancet HIV, Jennifer Smith and colleagues3 
provide an insightful analysis into how this goal 
might be achieved. Clinical trials of HIV prevention 
strategies are designed to be shielded from many 
factors; one possible cause for the failure to eliminate 
HIV is underappreciation that these factors can aﬀ ect 
the implementation of such strategies in non-trial 
contexts, undermining the ability of trials to predict 
eﬀ ectiveness in the real world. A successful trial 
therefore is just an initial step in a process to build a 
scientiﬁ c understanding of how an intervention can be 
implemented in real contexts to alleviate HIV burden. 
Through a series of studies culminating in this 
analysis, Smith and colleagues’ research team has ﬁ lled 
a major knowledge gap by translating the measured 
eﬃ  cacy of antiretroviral therapy (the most promising 
HIV intervention) into a viable and cost-eﬀ ective com-
munity-based strategy to control HIV and its disease 
burden. The line of evidence started with observational 
studies establishing that community-based home HIV 
testing and counselling (HTC) is feasible to achieve 
high coverage of HIV testing, point-of-care CD4 count 
testing, linkage to care, antiretroviral therapy initiation, 
and viral suppression.4,5 Detailed ﬁ eld work allowed 
the investigators to collect data about demographic 
characteristics, behaviour, CD4 cell count distribution, 
care before initiation of antiretroviral therapy, and 
treatment uptake. Although these observational 
studies established the feasibility of this approach, 
they raised questions about cost-eﬀ ectiveness and cost 
implications of community-based HTC.
The team proceeded to do a microcosting study from 
a provider perspective, and collected comprehensive 
real-world costing data. With this accumulation of 
community-based evidence, they were in position 
to build an individual-based mathematical model 
grounded in realism to assess the population-level 
eﬀ ect and cost-eﬀ ectiveness of this intervention 
strategy. The investigators used population-level viral 
suppression after the intervention as a biomarker for 
adherence to antiretroviral therapy, and were able to 
estimate the eﬀ ect of the intervention on HIV incidence. 
Their ﬁ ndings are remarkable: the intervention was very 
cost-eﬀ ective at all eligibility criteria for antiretroviral 
therapy, and the model’s ﬁ ndings suggested that it 
could help to achieve ambitious targets for incidence 
reduction and treatment, thereby reducing morbidity, 
mortality, and onwards transmission of HIV. The costs 
were driven mainly by drug prices; through reduction 
of these prices, which are higher in South Africa than 
in the rest of Africa, the intervention would be more 
cost eﬀ ective. 
These results are encouraging, but the public health 
eﬀ ect might actually have been underestimated. Smith 
and colleagues used a short time horizon (a decade), with 
most of the eﬀ ect tilted towards incidence reduction 
rather than prevention of morbidity and mortality. The 
long-term eﬀ ects of the intervention are thus likely to 
be more favourable than this analysis suggests. In short, 
community-based HTC is a viable and cost-eﬀ ective 
strategy. The UNAIDS 90-90-90 treatment targets by 
20206 are ambitious, but probably not far from what 
could be achieved in actual communities in at least 
parts of Africa.
This line of studies provided an excellent example of 
implementation science that takes a new intervention 
and uses it in communities. The relevance of this 
approach could go beyond HIV to other global health 
challenges.7 Such analyses might reduce the need 
for costly longitudinal assessments of the eﬀ ects of 
interventions and provide estimates earlier than would 
be possible with ﬁ eld studies. 
The results of Smith and colleagues’ analysis might 
be applicable in other settings in Africa, particularly 
those with comparable HIV prevalence, but lower anti-
retroviral therapy cost. Yet, this approach needs to be 
replicated in other settings beyond South Africa, to 
have a better picture of what can be achieved in the 
near and intermediate terms. The rollout of this strategy 
should also factor in the spatial structure of infection 
distribution, and prioritise regions with high density of 
HIV infection.8,9 Cost-eﬀ ectiveness in small communities 
with high HIV prevalence might not translate into 
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cost-eﬀ ectiveness across larger geographic areas that 
encompass various epidemics.
Voluntary programmes and provider-initiated services 
cannot achieve the coverage needed to make a decisive 
eﬀ ect on the epidemic. Social and community engage-
ment, for example through community-based HTC, 
is an essential ingredient to achieve HIV eli mination. 
With its low infrastructure demands, community-
based HTC and linkage to care can be easily and rapidly 
scaled up. Evidence also points to the acceptability 
of community-based HTC in diverse settings.10,11 The 
drawbacks for community public health programmes 
are often their cost and logistics, but these factors might 
not be as much of a concern in the HIV hyperepidemics 
of sub-Saharan Africa. The scale of epidemics is large and 
justiﬁ es a proportionate investment of resources, and 
evidence from Smith and colleagues’ study shows that 
the investment will be very cost-eﬀ ective. The diﬀ usion 
of a community culture of health-seeking behaviour 
might also aﬀ ect other health outcomes.
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